EP0455510A3 - Use of 5-ht1a receptor agonist compounds for inhibiting gastric acid secretion - Google Patents

Use of 5-ht1a receptor agonist compounds for inhibiting gastric acid secretion Download PDF

Info

Publication number
EP0455510A3
EP0455510A3 EP19910304047 EP91304047A EP0455510A3 EP 0455510 A3 EP0455510 A3 EP 0455510A3 EP 19910304047 EP19910304047 EP 19910304047 EP 91304047 A EP91304047 A EP 91304047A EP 0455510 A3 EP0455510 A3 EP 0455510A3
Authority
EP
European Patent Office
Prior art keywords
gastric acid
acid secretion
receptor agonist
inhibiting gastric
agonist compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19910304047
Other versions
EP0455510A2 (en
EP0455510B1 (en
Inventor
Jaswant Singh Gidda
John Mehnert Schaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP0455510A2 publication Critical patent/EP0455510A2/en
Publication of EP0455510A3 publication Critical patent/EP0455510A3/en
Application granted granted Critical
Publication of EP0455510B1 publication Critical patent/EP0455510B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides a method of inhibiting gastric acid secretion in mammals by administering a 5-HT1A agonist compound or a pharmaceutically acceptable salt thereof.
EP91304047A 1990-05-04 1991-05-03 Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion Expired - Lifetime EP0455510B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US519388 1990-05-04
US07/519,388 US5096908A (en) 1990-05-04 1990-05-04 Method of inhibiting gastric acid secretion

Publications (3)

Publication Number Publication Date
EP0455510A2 EP0455510A2 (en) 1991-11-06
EP0455510A3 true EP0455510A3 (en) 1992-05-06
EP0455510B1 EP0455510B1 (en) 1996-11-27

Family

ID=24068110

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91304047A Expired - Lifetime EP0455510B1 (en) 1990-05-04 1991-05-03 Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion

Country Status (14)

Country Link
US (1) US5096908A (en)
EP (1) EP0455510B1 (en)
JP (1) JPH04270219A (en)
KR (5) KR0182791B1 (en)
AT (1) ATE145553T1 (en)
AU (1) AU640003B2 (en)
CA (1) CA2040248C (en)
DE (1) DE69123286T2 (en)
DK (1) DK0455510T3 (en)
ES (1) ES2094792T3 (en)
GR (1) GR3022466T3 (en)
HU (1) HU217835B (en)
PH (1) PH27223A (en)
ZA (1) ZA913363B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229410A (en) * 1990-08-15 1993-07-20 Eli Lilly And Company 6-substituted-hexahydrobenz[cd]indoles
US5229409A (en) * 1990-08-15 1993-07-20 Eli Lilly And Company 6-substituted-tetrahydrobenz[cd]indoles
US5244911A (en) * 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz(cd)indoles and pharmaceutical use thereof
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5824680A (en) * 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
EP0543584B1 (en) * 1991-11-18 1996-05-22 Lilly Industries Limited Benzo(b)thiophene-2-carboxamides for the treatment of disorders of the central nervous system
US5330762A (en) * 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
GB9218113D0 (en) * 1992-08-26 1992-10-14 Lilly Industries Ltd Pharmaceutical compounds
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
NZ314570A (en) * 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
IT1271404B (en) * 1993-08-09 1997-05-28 Hi Chem S P A OXYMIC DERIVATIVES OF FORMYLPHENYLACETAMIDE-CEPHALOSPORANIC ACID
FR2712808B1 (en) * 1993-11-25 1996-02-16 Esteve Labor Dr Use of 1- {4- [4-aryl (or heteroaryl) -1-piperazinyl] -butyl} -1-H-azole derivatives for the preparation of medicaments for the treatment of disorders of gastric secretion.
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
CA2202879C (en) 1994-10-21 2005-08-30 Bradford C. Van Wagenen Calcium receptor-active compounds
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
ES2201300T3 (en) * 1996-05-01 2004-03-16 Nps Pharmaceuticals, Inc. ACTIVE COMPOUNDS AGAINST INORGANIC ION RECEIVERS.
WO2000004012A1 (en) 1998-07-17 2000-01-27 Synaptic Pharmaceutical Corporation COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF
AU2002218505A1 (en) * 2000-11-30 2002-06-11 Senju Pharmaceutical Co. Ltd. Pancreatitis remedies and medicines for prevention and therapy of reflux esophagitis
FR2817257B1 (en) * 2000-11-30 2009-03-20 Sanofi Synthelabo CYCLOHEXYL (ALKYL) -PROPANOLAMINES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE10358004A1 (en) * 2003-12-11 2005-07-14 Abbott Gmbh & Co. Kg Ketolactam compounds and their use
WO2010021149A1 (en) * 2008-08-21 2010-02-25 武田薬品工業株式会社 Spiro compound capable of inhibiting acid secretion
EP2338873A1 (en) * 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906757A (en) * 1959-09-29 Their preparation
US2922744A (en) * 1957-06-26 1960-01-26 Lilly Co Eli Therapeutic processes employing aminobenzodioxane medicaments
DE1668055B2 (en) * 1967-03-10 1973-09-06 Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt BASIC SUBSTITUTED CYCLOPENTYLPHENOLETHERS, THEIR SALT WITH PHYSIOLOGICALLY COMPATIBLE ACIDS AND PROCESS FOR THEIR PRODUCTION
US4507303A (en) * 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
DE3321969A1 (en) * 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-PYRIMIDINYL-1-PIPERAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THE SAME
DE3346573A1 (en) * 1983-12-23 1985-07-04 Troponwerke GmbH & Co KG, 5000 Köln 1,3,4,5-TETRAHYDROBENZ (C, D) INDOLE, A METHOD FOR THE PRODUCTION AND THEIR USE
IL74222A (en) * 1984-02-06 1988-07-31 Lilly Co Eli 6-substituted-4-dialkylamino tetrahydrobenz(c,d)indoles,their preparation and pharmaceutical compositions comprising them
US4576959A (en) * 1984-02-06 1986-03-18 Eli Lilly And Company 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles
AR241161A1 (en) * 1984-07-30 1991-12-30 Merrelll Dow Pharmaceuticals I "PROCEDURE FOR THE PREPARATION OF SUBSTITUTED N-AMINOALKYLEN DERIVATIVES OF GLUTARIMIDE"
DE3719924A1 (en) * 1986-12-22 1988-06-30 Bayer Ag 8-SUBSTITUTED 2-AMINOTETRALINE
US4745126A (en) * 1987-03-12 1988-05-17 Eli Lilly And Company Method of treating anxiety with tetrahydrobenz[c,d]indole-6-carboxamides
EP0306375A1 (en) * 1987-08-07 1989-03-08 Synthelabo 2-[(4-Piperidinyl)methyl]-1,2,3,4-tetrahydroisoquinoline derivatives, their preparation and their use in therapy
CA1331191C (en) * 1988-03-25 1994-08-02 Bengt Ronny Andersson Therapeutically useful tetralin derivatives
US4845221A (en) * 1988-04-15 1989-07-04 American Home Products Corporation Serotonergic substituted piperazinyl tetralins
CA1336911C (en) * 1988-06-03 1995-09-05 David Taiwai Wong Serotonin antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 79, nos. 1-2, 1982, pages 105-110, Elsevier Biomedical Press; M. MAEDA-HAGIWARA et al.: "Gastric secretagogue action of ergot alkaloids in the perfused stomach of anesthetized rats" *
THE JOURNAL OF PHYSIOLOGY, vol. 141, no. 1, 3rd April 1958, pages 27-34, Cambridge University Press, London, GB; J.W. BLACK et al.: "The effects of 5-hydroxytryptamine on gastric secretion in anaestheized dogs" *

Also Published As

Publication number Publication date
ZA913363B (en) 1993-01-27
PH27223A (en) 1993-05-04
JPH04270219A (en) 1992-09-25
AU640003B2 (en) 1993-08-12
ATE145553T1 (en) 1996-12-15
KR0182791B1 (en) 1999-05-01
KR100188373B1 (en) 1999-06-01
EP0455510A2 (en) 1991-11-06
KR100189590B1 (en) 1999-06-01
HUT60918A (en) 1992-11-30
KR100188375B1 (en) 1999-06-01
HU217835B (en) 2000-04-28
HU911499D0 (en) 1991-11-28
ES2094792T3 (en) 1997-02-01
DK0455510T3 (en) 1997-04-28
EP0455510B1 (en) 1996-11-27
CA2040248A1 (en) 1991-11-05
KR100188372B1 (en) 1999-06-01
CA2040248C (en) 2001-06-19
KR910019615A (en) 1991-12-19
DE69123286D1 (en) 1997-01-09
AU7607991A (en) 1991-11-07
US5096908A (en) 1992-03-17
DE69123286T2 (en) 1997-04-24
GR3022466T3 (en) 1997-05-31

Similar Documents

Publication Publication Date Title
GR3022466T3 (en) Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion
PT80717A (en) Process for preparing benzodiazepine analogs
PL331922A1 (en) Method of inhibiting fibrosis by means of an antagonist of somatotropin release inhibiting factor
EP0342541A3 (en) Retroviral protease inhibitors
HK83697A (en) Methanoanthracenes as dopamine antagonists
ITMI920045A0 (en) RAILLAYING MACHINE FOR THE CONTROLLED LOWERING OF A RAIL
TW222265B (en)
EG18586A (en) Cycloalkylamides of(beta,beta)-1-alkyl-6-(substituted)ergolines
PL308635A1 (en) Glucopyranosidic derivatives of bezothiophenols, pharmaceutical compositions containing them and method of obtaining such derivatives
EP0521393A3 (en) Diclofenac salt, a method for the preparation thereof and pharmaceutical compositions containing it
EP0328282A3 (en) Pharmaceutical
ZA916918B (en) Amino acid analogs as CCK antagonists.
PL246418A1 (en) Process for preparing n-/3-trifluoromethylphenyl/-n'-propargylpiperazine
ZA927307B (en) Method for treating hypertension
HUT40110A (en) Process for preparing indole derivatives
SE9404192D0 (en) New process
IL109227A0 (en) Leustroducsin h, pharmaceutical composition containing the same, and processes for the preparation thereof
UA19166A1 (en) Herbicidal composition
ITMI910953A0 (en) ELECTROCHEMICAL PROCEDURE FOR THE PREPARATION OF LACTAMS NOT REPLACED BY NITROGEN

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910515

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

D17Q First examination report despatched (deleted)
GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 145553

Country of ref document: AT

Date of ref document: 19961215

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

ET Fr: translation filed
REF Corresponds to:

Ref document number: 69123286

Country of ref document: DE

Date of ref document: 19970109

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2094792

Country of ref document: ES

Kind code of ref document: T3

ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3022466

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20030331

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20030401

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20030402

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20030403

Year of fee payment: 13

Ref country code: DK

Payment date: 20030403

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20030422

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20030505

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20030506

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20030522

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20030530

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20030605

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20030617

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040503

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040503

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040504

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040504

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040531

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040601

BERE Be: lapsed

Owner name: *ELI LILLY AND CY

Effective date: 20040531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041201

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041203

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20040503

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050131

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20041201

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050503

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20040504